Bernheim J, Arendt C, de Vos C
UCB Pharmaceutical Sector, R & D, Chemin du Foriest, Braine l'Alleud, Belgium.
Agents Actions Suppl. 1991;34:269-93.
Cetirizine, a metabolite of hydroxyzine, is an antihistamine with as distinguishing features: 1) exquisite anti-H1 specificity: cetirizine appears unique in being devoid of action on receptors other than the H1 receptor; 2) potency: at unit dose it is the most potent antihistamine in the skin and the lung; 3) absence of metabolism. These three characteristics suggest that cetirizine be considered the choice H1 antagonist for experiments on the immediate allergic reaction. Cetirizine additionally in vitro inhibits the migration of eosinophils, and in vivo, in the skin, the infiltration by eosinophils that is characteristic for the late phase allergic reaction. Other antihistamines are less active or inactive with respect to this property. According to several lines of evidence, the effect of cetirizine on eosinophils is unlikely to be due to H1 antagonism, but is more likely a novel property of the compound.
西替利嗪是羟嗪的代谢产物,是一种抗组胺药,具有以下显著特征:1)对H1受体具有高度特异性:西替利嗪似乎独一无二,对H1受体以外的其他受体没有作用;2)效力:在单位剂量下,它是皮肤和肺部中效力最强的抗组胺药;3)无代谢。这三个特征表明,西替利嗪应被视为用于速发型过敏反应实验的首选H1拮抗剂。此外,西替利嗪在体外可抑制嗜酸性粒细胞的迁移,在体内,在皮肤中,可抑制嗜酸性粒细胞的浸润,而嗜酸性粒细胞浸润是迟发型过敏反应的特征。其他抗组胺药在这一特性方面活性较低或无活性。根据多条证据,西替利嗪对嗜酸性粒细胞的作用不太可能是由于H1拮抗作用,而更可能是该化合物的一种新特性。